Intellia, expanding in gene editing, buys startup Rewrite for $45M
Dive Brief:
Intellia Therapeutics, a leading developer of CRISPR-based medicines, on Thursday said it will buy privately held Rewrite Therapeutics for $45 million,...
Continue Reading →
